Cannabis Use, Cannabis Smoking, Marijuana Smoking, Marijuana Usage
Conditions
Brief summary
This is a longitudinal study of the long-term health impact of cannabis smoking on the lungs. Participants will be followed over a period of 3 years, and impacts of cannabis smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.
Detailed description
This is a longitudinal study of the long-term lung health impact of cannabis smoking in adults using xenon-129 (129Xe) MRI over three years. Males and females between the ages of 18 to 85 years with a history of cannabis smoking will be screened, and those who satisfy all inclusion and exclusion criteria will undergo study visits for up to 3 years, with visits every 12 ± 3 months, for a total of up to four study visits. Each study visit will include collection of patient smoking history and vital signs. At Visit 1 and 4, 129-Xe MRI, spirometry, plethysmography for airways resistance (Raw) and lung volumes, forced oscillation technique (FOT) and multiple breath nitrogen washout (MBNW) for the lung clearance index (LCI) will all be performed pre- and post-bronchodilator. Blood will be drawn for blood eosinophil count, and sputum induction will be done to measure sputum eosinophils. A CT will also be done at Robarts Research Institute, or at University Hospital, London Health Sciences Centre next door to Robarts. Visit 2 will be a telephone call to complete questionnaires. Visit 3 will include spirometry and questionnaires only. Participants 35 years of age or older will complete a six minute walk test (6MWT) for the distance walked (6MWD), pre and post oxygen saturation, perceived dyspnea (Modified Borg Scale) and perceived exertion (Borg's rating of perceived exertion). These participants will complete the St. George's Respiratory Questionnaire (SGRQ). Participants under the age of 35 will complete Cardio Pulmonary Exercise Testing to assess exercise capacity, and the American Thoracic Society Questionnaire (ATSQ).
Interventions
DIAGNOSTIC_TESTHyperpolarized Xenon-129 MRI of the lungs
Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
DIAGNOSTIC_TESTComputed Tomography (CT)
Participants will undergo a CT scan of the thoracic cavity
DIAGNOSTIC_TESTPulmonary Function Tests (PFTs)
Participants will have their lung function evaluated using PFTs
DIAGNOSTIC_TESTSix Minute Walk Test (6MWT)
Participants \>35 years of age will perform the six minute walk test as a measure of exercise capacity
DIAGNOSTIC_TESTCardiopulmonary exercise testing (CPET)
Participants \<35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
DIAGNOSTIC_TESTSputum analysis
Participants will provide a sputum sample that will be analysed for eosinophils
DIAGNOSTIC_TESTBlood analysis
Participants will have their blood drawn and analysed for eosinophil count.
Sponsors
Western University, Canada
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature * Provision of written, informed consent prior to any study specific procedures * Males and females aged 18-85 * Current or former cannabis smoker (medicinal or recreational) with or without concurrent tobacco smoking history * Participant is able to perform reproducible pulmonary function testing (i.e. the 3 best acceptable spirograms have Forced Expiratory Volume in 1 second (FEV1) values that do not vary more than 150 millilitres) * Participant is able to perform a breathhold for 16s * FEV1 \> 25% predicted * Forced Vital Capacity (FVC) \> 25% predicted and \>0.5 litres
Exclusion criteria
* Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand written material * Participant is medically unstable in the opinion of the Principal Investigator * Participant has a daytime room air oxygen saturation \<90% while lying supine * Participant is unable to perform spirometry or plethysmography maneuvers * Patient is pregnant at time of enrolment * In the opinion of the investigator, patient suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia * Patient has implanted mechanically, electrically or magnetically activated device or any metal in their body, which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) - at the discretion of the MRI Technologist.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differences in parenchyma between cannabis-only smokers and cannabis and tobacco smokers | 3 years | Measured using 129-Xe MRI |
| Dose-response of cannabis use to changes in airways over time | 3 years | Measured using 129-Xe MRI |
| Dose-response of cannabis use to changes in parenchyma over time | 3 years | Measured using 129-Xe MRI |
| Changes in airways over time | 3 years | Measured using Xenon-129 (129-Xe) MRI |
| Changes in parenchyma over time | 3 years | Measured using Xenon-129 (129-Xe) MRI |
| Differences in lung ventilation in cannabis smokers compared to never-smokers and tobacco smokers | 3 years | Measured using 129-Xe MRI |
| Differences in perfusion in cannabis smokers compared to never-smokers and tobacco smokers | 3 years | Measured using 129-Xe MRI |
| Differences in parenchyma integrity in cannabis smokers compared to never-smokers and tobacco smokers | 3 years | Measured using 129-Xe MRI |
| Differences in airways between cannabis-only smokers and cannabis and tobacco smokers | 3 years | Measured using 129-Xe MRI |
Countries
Canada
Contacts
Primary ContactGrace E Parraga, PhD
Backup ContactAngela P Wilson, RRT
Outcome results
None listed